3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
46
Burkitt Lymphoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Recurrence
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Smoldering Multiple Myeloma
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia
2
Down Syndrome
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thalassemia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Oropharyngeal Neoplasms
1
Interventions
Prednisone
4
Docetaxel
4
enzalutamide
2
olaparib
1
niraparib
1
ibrutinib
1
fludrocortisone acetate
1
darolutamide
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pluvicto
1
Pioglitazone
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
Dexamethasone
×
30 days
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled